Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 76

Publication Record

Connections

Human papillomavirus vaccination completion rates among gynecological providers: an institutional retrospective review.
Elsamadicy EA, Schneiter MK, Hull PC, Khabele D
(2019) Hum Vaccin Immunother 15: 1851-1855
MeSH Terms: Adult, Female, Gynecology, Health Knowledge, Attitudes, Practice, Humans, Papillomavirus Infections, Papillomavirus Vaccines, Patient Acceptance of Health Care, Physicians, Practice Patterns, Physicians', Retrospective Studies, Vaccination, Young Adult
Show Abstract · Added July 11, 2019
: The primary aim of this study is to assess and characterize correlates of human papillomavirus (HPV) vaccine series completion among young adult women evaluated by gynecological (GYN) providers at a single institution and to measure changes over 4-y period. : At a major academic center, the medical records of 845 women administered the HPV vaccine series by a GYN provider were retrospectively reviewed from 2006 to 2010 and 2014 to 2015. Patients were grouped based on the date of vaccine initiation into "earlier" (2006-2010) and "later" (2014-2015) cohorts. Patient demographics, dates of vaccine administration, and practice locations where vaccines were administered were collected. Patients who received all 3 vaccines within 6 months were deemed "complete". Patients seen by a provider but did not receive the vaccination were deemed "missed opportunities". The primary outcome was completion of HPV vaccination according to the ACIP guidelines. : The 845 patients were divided into earlier (n = 399) and later (n = 446) cohorts. There was no statistically significant difference in completion rates between the earlier-cohort compared to the later-cohort (). Age at initiation were similar (), with the complete cohort having a significantly lower body mass index (BMI) than the incomplete cohort (). There was a significant difference between the completion rates among race/ethnic groups ( = .036). African-American and Hispanic ( patient-populations had the lowest completion rates and higher missed opportunities. : Our study found an overall low completion rate in both earlier and later cohorts. Additionally, higher BMI and African-American and Hispanic race/ethnicity were associated with low vaccine completion.
0 Communities
1 Members
0 Resources
13 MeSH Terms
Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer.
Mirghani H, Lang Kuhs KA, Waterboer T
(2018) Oral Oncol 82: 108-114
MeSH Terms: Alphapapillomavirus, Antibodies, Viral, Biomarkers, Tumor, DNA, Viral, Humans, Neoplasm Recurrence, Local, Oropharyngeal Neoplasms, Papillomavirus Infections, Saliva
Show Abstract · Added March 20, 2020
One of the major concerns in oncology lies in the ability to detect recurrences at their earliest stage to increase the likelihood of cure following second line, or salvage, therapy. Although human papillomavirus (HPV)-driven oropharyngeal cancers have a good prognosis, 20-25% of patients will recur within 5 years of treatment and a significant portion will die from their disease. In recent years, great effort has been put toward evaluating the potential clinical utility of HPV-related biomarkers for early diagnosis of recurrent disease. Indeed, following completion of treatment, detection of HPV-DNA in oral rinses or blood and serologic assays against HPV oncoproteins could be helpful to track residual disease or recurrence. Several recent studies have reported promising findings, thus potentially paving the way for the use of biomarkers in the management of HPV-OPC. In this review, we evaluate and discuss the current knowledge on this topic and provide some directions for future research.
Copyright © 2018 Elsevier Ltd. All rights reserved.
0 Communities
1 Members
0 Resources
MeSH Terms
Operationalizing outcome measures of human papillomavirus vaccination among adolescents.
Odoh C, Sanderson M, Williams EA, Hull PC
(2018) Public Health 159: 129-132
MeSH Terms: Adolescent, Cross-Sectional Studies, Female, Health Care Surveys, Humans, Immunization Schedule, Male, Outcome Assessment, Health Care, Papillomavirus Infections, Papillomavirus Vaccines, Time Factors, Vaccination
Show Abstract · Added July 11, 2019
OBJECTIVES - When examining vaccination coverage, researchers must make decisions about how to define outcome measures based on many factors, including the timing of doses. Different operationalizations of the same outcome can often lead to different findings and can affect the ability to make comparisons across studies. This methodological article aimed to illustrate the implications of two options for operationalizing human papillomavirus (HPV) vaccination based on timing: initiation of the first dose at any age vs before the 13th birthday (on time).
STUDY DESIGN - Cross-sectional observational design.
METHODS - The 2014 National Immunization Survey for Teens (N = 16,439 adolescents aged 13-17 years) was analyzed using multivariate logistic regression for each outcome measure and effect modification by gender.
RESULTS - Age was positively associated with initiation at any age but negatively associated with on-time initiation. Gender modified the effect of race/ethnicity for both measures of initiation, but the pattern across groups was different for the two outcomes. Gender modified the effect of provider recommendation for initiation at any age, while gender modified the effects of age and region for on-time initiation.
CONCLUSION - Decisions of how to operationalize outcomes of HPV vaccine initiation among adolescents can lead to different conclusions about the role of age and gender differences for several predictive variables. To inform the development of public health efforts that promote on-time HPV vaccination among male and female adolescents, researchers should consider the importance of dose timing when operationalizing outcome measures. We recommend including on-time receipt of the HPV vaccine as an outcome measure.
Copyright © 2018 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
0 Communities
1 Members
0 Resources
12 MeSH Terms
Re: Human papillomavirus vaccine initiation in Asian Indians and Asian subpopulations: a case for examining disaggregated data in public health research.
Shing JZ, Harris CR, Hull PC
(2018) Public Health 160: 162-163
MeSH Terms: Asian Continental Ancestry Group, Humans, Papillomavirus Infections, Papillomavirus Vaccines, Public Health
Added July 11, 2019
0 Communities
1 Members
0 Resources
MeSH Terms
Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: Challenges in detecting dysplasia.
Adkins BD, Barlow AB, Jack A, Schultenover SJ, Desouki MM, Coogan AC, Weiss VL
(2018) Cytopathology 29: 281-287
MeSH Terms: Androgens, Atypical Squamous Cells of the Cervix, Cervical Intraepithelial Neoplasia, Cervix Uteri, Ectodermal Dysplasia, Female, Humans, Papanicolaou Test, Papillomavirus Infections, Retrospective Studies, Squamous Intraepithelial Lesions of the Cervix, Transgender Persons, Uterine Cervical Neoplasms, Vaginal Smears
Show Abstract · Added April 15, 2019
INTRODUCTION - The characteristic features of Papanicolaou (Pap) tests collected from female-to-male (FTM) transgender patients on androgen therapy have not been well defined in the literature. FTM transgender patients require cervical cancer screening with the same recommended frequency as cis-gender females. Dysplasia remains challenging to differentiate from atrophy. Without pertinent history, the atrophic findings in younger transgender patients can be misinterpreted as high-grade dysplasia.
METHODS - A review of all cervical Pap tests of transgender patients receiving androgen therapy (2010-2017) was performed. Bethesda diagnosis, cytomorphological features, HPV testing and cervical biopsy results were reviewed.
RESULTS - Eleven transgender patients receiving androgen therapy were identified with 23 cervical Pap tests, 11 HPV tests and five cervical biopsies performed. A review of the Pap tests demonstrated: 57% negative for intraepithelial lesion; 13% unsatisfactory; 13% atypical squamous cells of undetermined significance; 13% atypical squamous cells - cannot exclude high-grade squamous intraepithelial lesion; and 4% high-grade squamous intraepithelial lesion. The rates of abnormal tests were higher than our age-matched cis-gender atrophic cohort rates of unsatisfactory (0.5%), atypical squamous cells of undetermined significance (7%), atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (0%) and high-grade squamous intraepithelial lesion (0.5%). The cytological findings from liquid-based preparations included dispersed and clustered parabasal-type cells, scattered degenerated cells, smooth evenly dispersed chromatin, and occasional mild nuclear enlargement and irregularity. Dysplastic cells had larger nuclei, hyperchromatic clumped chromatin, and more irregular nuclear contours.
CONCLUSIONS - The evaluation of dysplasia can be challenging on Pap tests from transgender patients on androgen therapy. The cohort evaluated had higher rates of unsatisfactory and abnormal Pap tests. Pathologists should be familiar with the distinctive cytomorphological changes in the Pap tests from patients on androgen therapy to evaluate them appropriately.
© 2018 John Wiley & Sons Ltd.
0 Communities
1 Members
0 Resources
14 MeSH Terms
T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study.
Lang Kuhs KA, Lin SW, Hua X, Schiffman M, Burk RD, Rodriguez AC, Herrero R, Abnet CC, Freedman ND, Pinto LA, Hamm D, Robins H, Hildesheim A, Shi J, Safaeian M
(2018) PLoS One 13: e0178167
MeSH Terms: Case-Control Studies, Cervical Intraepithelial Neoplasia, Cohort Studies, Female, Human papillomavirus 16, Humans, Papillomavirus Infections, Receptors, Antigen, T-Cell, Reproducibility of Results, Uterine Cervical Neoplasms, VDJ Recombinases
Show Abstract · Added March 20, 2020
BACKGROUND - It is unknown why a minority of women fail to clear human papillomavirus (HPV) and develop precancer/cancer. Differences in T-cell receptor (TCR) repertoires may identify HPV16-infected women at highest-risk for progression to cancer. We conducted a proof-of-principle study nested within the Guanacaste HPV Natural History Study to evaluate the utility of next-generation sequencing for interrogating the TCR repertoires among women who cleared and failed to clear cervical HPV16.
METHODS - TCR repertoires of women with HPV16-related intraepithelial neoplasia grade 3 or higher (CIN3+; n = 25) were compared to women who cleared an incident HPV16 infection without developing precancer/cancer (n = 25). TCR diversity (richness and evenness) and relative abundance (RA) of gene segment (V [n = 51], D [n = 2], J [n = 13]) usage was evaluated; receiver operating curve analysis assessed the ability to differentiate case-control status.
RESULTS - TCR repertoire richness was associated with CIN3+ status (P = 0.001). Relative abundance (RA) of V-gene segments was enriched for associations between cases and controls. A single V-gene (TRBV6-7) was significantly associated with CIN3+ status (RA = 0.11%, 0.16%, among cases and controls, respectively, Bonferroni P = 0.0008). The estimated area under the curve using richness and V-gene segment RA was 0.83 (95% confidence interval: 0.73-0.90).
CONCLUSIONS - Substantial differences in TCR repertoire among women with CIN3+ compared to women who cleared infection were observed.
IMPACT - This is the first study to use next-generation sequencing to investigate TCR repertoire in the context of HPV infection. These findings suggest that women with HPV16-associated cervical lesions have significantly different TCR repertoires from disease-free women who cleared HPV16 infection.
0 Communities
1 Members
0 Resources
MeSH Terms
Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Lang Kuhs KA, Kreimer AR, Trivedi S, Holzinger D, Pawlita M, Pfeiffer RM, Gibson SP, Schmitt NC, Hildesheim A, Waterboer T, Ferris RL
(2017) Cancer 123: 4382-4390
MeSH Terms: Antibodies, Viral, Cell Transformation, Viral, Female, Human papillomavirus 16, Humans, Immunohistochemistry, Male, Middle Aged, Oncogene Proteins, Viral, Oropharyngeal Neoplasms, Papillomavirus Infections, Predictive Value of Tests, Prognosis, Recurrence, Repressor Proteins, Sensitivity and Specificity
Show Abstract · Added October 23, 2017
BACKGROUND - Human papillomavirus 16 (HPV16) E6 antibodies may be an early marker of the diagnosis and recurrence of human papillomavirus-driven oropharyngeal cancer (HPV-OPC).
METHODS - This study identified 161 incident oropharyngeal cancer (OPC) cases diagnosed at the University of Pittsburgh (2003-2013) with pretreatment serum. One hundred twelve had preexisting clinical HPV testing with p16 immunohistochemistry and HPV in situ hybridization (87 were dual-positive [HPV-OPC], and 25 were dual-negative [HPV-negative]); 62 had at least 1 posttreatment serum sample. Eighty-six of the 161 tumors were available for additional HPV16 DNA/RNA testing (45 were dual-positive [HPV16-OPC], and 19 were dual-negative [HPV16-negative). HPV16 E6 antibody testing was conducted with multiplex serology. The following were evaluated: 1) the sensitivity and specificity of HPV16 E6 serology for distinguishing HPV-OPC and HPV16-OPC from HPV-negative OPC, 2) HPV16 E6 antibody decay after treatment with linear models accommodating correlations in variance estimates, and 3) pre- and posttreatment HPV16 E6 levels and the risk of recurrence with Cox proportional hazards models.
RESULTS - Seventy-eight of 87 HPV-OPCs were HPV16 E6-seropositive (sensitivity, 89.7%; 95% confidence interval [CI], 81.3%-95.2%), and 24 of 25 HPV-negative OPCs were HPV16 E6-seronegative (specificity, 96.0%; 95% CI, 79.6%-99.9%). Forty-two of 45 HPV16-OPCs were HPV16 E6-seropositive (sensitivity, 93.3%; 95% CI, 81.7%-98.6%), and 18 of 19 HPV16-negative OPCs were HPV16 E6-seronegative (specificity, 94.7%; 95% CI, 74.0%-99.9%). Posttreatment HPV16 E6 antibody levels did not decrease significantly from the baseline (P = .575; median follow-up, 307 days) and were not associated with the risk of recurrence. However, pretreatment HPV16 E6 seropositivity was associated with an 86% reduced risk of local/regional recurrence (hazard ratio, 0.14; 95% CI, 0.03-0.68; P = .015).
CONCLUSIONS - HPV16 E6 antibodies may have potential clinical utility for the diagnosis and/or prognosis of HPV-OPC. Cancer 2017;123:4382-90. © 2017 American Cancer Society.
© 2017 American Cancer Society.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Concordance of Beta-papillomavirus across anogenital and oral anatomic sites of men: The HIM Study.
Nunes EM, López RVM, Sudenga SL, Gheit T, Tommasino M, Baggio ML, Ferreira S, Galan L, Silva RC, Lazcano-Ponce E, Giuliano AR, Villa LL, Sichero L, HIM Study group
(2017) Virology 510: 55-59
MeSH Terms: Anal Canal, Betapapillomavirus, Brazil, Florida, Genitalia, Male, Genotype, Genotyping Techniques, Homosexuality, Male, Humans, Male, Mexico, Mouth Mucosa, Papillomavirus Infections
Show Abstract · Added August 15, 2017
We evaluated the concordance between β-HPVs detected in external genital skin, anal canal, and oral cavity specimens collected simultaneously from 717 men that were participating in the multinational HIM Study. Viral genotyping was performed using the Luminex technology. Species- and type-specific concordance was measured using kappa statistics for agreement. Overall, concordance of β-HPVs across sites was low and mainly observed among paired genital/anal canal samples. When grouped by species, solely β-4 HPVs showed moderate concordance in genital/anal pairs (κ = 0.457), which could be attributed to the substantial concordance of HPV-92 in men from Brazil and Mexico (κ > 0.610). β-HPV type concordance was higher in Mexico, where HPV-19 was consistently concordant in all anatomic site combinations. Our analysis indicates that type-specific concordance across sites is limited to few viral types; however, these infections seem to occur more often than would be expected by chance, suggesting that although rare, there is agreement among sites.
Copyright © 2017 Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
13 MeSH Terms
The Natural History of Oral Human Papillomavirus in Young Costa Rican Women.
Beachler DC, Lang Kuhs KA, Struijk L, Schussler J, Herrero R, Porras C, Hildesheim A, Cortes B, Sampson J, Quint W, Gonzalez P, Kreimer AR
(2017) Sex Transm Dis 44: 442-449
MeSH Terms: Adult, Costa Rica, Female, Human Papillomavirus DNA Tests, Humans, Longitudinal Studies, Oropharyngeal Neoplasms, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Prevalence, Randomized Controlled Trials as Topic, Stomatitis, Young Adult
Show Abstract · Added August 15, 2017
BACKGROUND - Oral human papillomavirus (HPV) infection and related oropharyngeal cancer are uncommon in lower-income countries, particularly compared to HPV-associated cervical cancer. However, little is known about the natural history of oral HPV in less-developed settings and how it compares to the natural history of cervical HPV.
METHODS - Three hundred fifty women aged 22 to 33 years from the Costa Rica Vaccine Trial provided exfoliated cells from the cervical and oral regions at 2 visits 2 years apart. Samples from both visits were tested for 25 characterized α HPV types by the SPF10 PCR-DNA enzyme immunoassay-LiPA25 version 1 system. Risk factors for oral HPV persistence were calculated utilizing generalized estimating equations with a logistic link.
RESULTS - Among the 82 women with characterized α oral HPV DNA detected at baseline, 14 persisted and were detected 2 years later (17.6%; 95% confidence interval [CI], 10.9-28.5%) and was similar to the persistence of α cervical HPV (40/223; 17.7%; 95% CI, 13.1-23.9%; P = 0.86). Acquisition of new α oral HPV type was low; incident infection (1.7%; 95% CI, 0.6-3.7%).
CONCLUSIONS - Oral HPV DNA is uncommon in young women in Latin America, and often appears to clear within a few years at similar rates to cervical HPV.
0 Communities
1 Members
0 Resources
14 MeSH Terms
Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.
Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim van der Loeff MF, van der Laan LE, Kipping S, Taylor D, Giuliano AR
(2018) Sex Transm Infect 94: 55-61
MeSH Terms: Adolescent, Alcohol Drinking, Chlamydia trachomatis, Coinfection, Female, Genotype, Gonorrhea, HIV Infections, HIV Seronegativity, Herpes Genitalis, Herpesvirus 2, Human, Humans, Medically Underserved Area, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Prevalence, Sexual Behavior, Sexual Partners, Sexually Transmitted Diseases, South Africa, Syphilis, Young Adult
Show Abstract · Added August 15, 2017
OBJECTIVE - To estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) trial.
METHODS - HIV-negative women aged 16-24 years old were enrolled in the EVRI trial (NCT01489527) and randomised to receive the licensed four-valent HPV vaccine or placebo. At study entry, participants were clinically evaluated for five STIs: herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis and disease-causing HPV genotypes (6/11/16/18/31/33/35/39/45/51/52/56/58/59/68). Demographic and sexual history characteristics were compared among women with STI co-infections, single infection and no infection using Pearson χ and Mann-Whitney tests. ORs were calculated to evaluate factors associated with STI co-infection prevalence.
RESULTS - Among 388 young women, STI co-infection prevalence was high: 47% had ≥2 concurrent STIs, 36% had a single STI and 17% had none of the five evaluated STIs. HPV/HSV-2 (26%) was the most prevalent co-infection detected followed by HPV/HSV-2/ (CT) (17%) and HPV/CT (15%). Co-infection prevalence was independently associated with alcohol use (adjusted OR=2.01, 95% CI 1.00 to 4.06) and having a sexual partner with an STI (adjusted OR=6.96, 95% CI 1.53 to 30.08).
CONCLUSIONS - Among high-risk young women from underserved communities such as in Southern Africa, a multicomponent prevention strategy that integrates medical and behavioural interventions targeting both men and women is essential to prevent acquisition of concurrent STI infections and consequent disease.
TRIAL REGISTRATION NUMBER - NCT01489527; Post-results.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
0 Communities
1 Members
0 Resources
23 MeSH Terms